Research progress of external therapies of traditional Chinese medicine in the treatment of non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease(NAFLD)is a common chronic liver disease characterized by diffuse hepatic steatosis.With the improvement of people's living standard,the incidence rate of NAFLD has been increasing,which has become one of the global health problems in 21st Century.However,there is no specific drug or standard treatment for NAFLD,which brings challenges to treatment.Acupuncture,moxibustion,massage and other external therapies based on the characteristics of traditional Chinese medicine have obvious curative effect in the clinical treatment of NAFLD,but the mechanism has not been systematically explained,which makes the clinical promotion evidence insufficient.This paper aims to summarize the researches on the treatment of NAFLD by external therapies of traditional Chinese medicine in recent years,and analyze its possible mechanism,so as to provide a scientific theoretical basis for future basic experiments and clinical research,and form a set of standardized clinical diagnosis and treatment scheme with the characteristics of traditional Chinese medicine.

Regulating effect of Chinese herbal medicine on the peritoneal lymphatic stomata in enhancing ascites absorption of experimental hepatofibrotic mice

AIM: To observe the regulatory effect of Chinese herbalmedicine on peritoneal lymphatic stomata and itssignificance in treating ascites in liver fibrosis model mice.METHODS: Two Chinese herbal composite prescriptionswere used separately to treat the carbon tetrachloride-induced mouse model of liver fibrosis. The histo-pathologicchanges of the liver sections (HE and VG stainings) wereobserved. The peritoneal lymphatic stomata was detected byscanning electron microscopy and computer imageprocessing. The changes of urinary volume and sodium ionconcentration were measured.RESULTS: In the model group, lots of fibrous tissue formedin liver and extended into the hepatic Iobulss to separatethem incompletely. In the treated and prevention groups,the histo-pathologic changes of liver was rather milder, onlyshowed much less fibrous tissue proliferation in the hepaticIobules. The peritoneal lymphatic stomata enlarged withincreased density in the experimental groups (diameter:PA, 3.07±0.69μm; PB, 2.82±0.37μm; TA, 3.25±0.82μmand TB, 2.82±0.56μm; density: PA, 7.11± 1.90 stomata@1000μm-2; PB, 8.76± 1.45 stomata@ 1000μm-2; TA, 6.55± 1.44 stomata@ 1000μm-2 and TB, 8.76 ± 1. 79 stomata@ 1000μm-2), as compared with the model group (diameter: 2.00 ±0.52μm; density: 4.45 ± 1. 05 stomata@ 1000 μm-2 ). Aftertreatment, the urinary volume and sodium ion excretionincreased in the experimental groupe ( PA, 231.28 ± 41. 09mmol@L-1; PB, 171.69± 27.48 mmol@L-1 and TA, 231.44±34.12 retool@ L-1 ), which were significantly different with thosein the model group (129.33 ± 36.75 rnmol@ L-1 ).CONCLUSION: Chinese herbal medicine has marked effectsin alleviating liver fibrosis, regulating peritoneal lymphaticstomata, improving the drainage of ascites from peritonealcavity and causing increase of urinary volume and sodiumion excretion to reduce the water and sodium retention, andthus have favorable therapeutic effect in treating ascites.

Advances in mesenchymal stem cells combined with traditional Chinese medicine therapy for liver fibrosis

Liver fibrosis is a primary cause of liver cirrhosis, and even hepatocarcinoma. Recently, the usage of mesenchyrnal stem cells （MSCs） has been investigated to improve liver fibrosis. It has been reported that the differentiation, proliferation and migration of MSCs can be regulated by traditional Chinese medicine treatment; however, the mechanisms are still unclear. In this article, the authors review the characteristics of MSCs such as multidirectional differentiation and homing, and its application in animal experiments and clinical trials. The authors also list areas that need further investigation, and look at the future prospects of clinical application of MSCs.

Study of the similarities and differences between TCM and Tujia medicine in clinical diagnosis and treatment of liver cancer

目前国内对于肝癌的治疗已经不仅仅局限于西医的放化疗。随着中国传统医学的发展,更多的患者选择中医进行保守治疗。中医作为我国传统医学,具有完善的理论体系及诊疗体系。土家族医学作为中华民族医学的一个分支,在疾病治疗方面拥有其独特的诊疗手段。在探索肝癌诊疗时,笔者发现,中医与土家医在治疗肝癌时具有异曲同工之效,故进行对比性整理与研究,以期为诊疗肝癌提供参考与借鉴。

Auricular therapy for chemotherapy-induced nausea and vomiting in cancer patients:Perspectives from the traditional zang-fu organs and meridians theory

This paper presents the theoretical background of using auricular therapy(AT)for managing chemotherapy-induced nausea and vomiting(CINV)from the perspectives of traditional zang-fu organs and meridian theory.The zang-fu organs of stomach,spleen and liver play a crucial role in regulating the gastrointestinal functions.The chemotherapeutic agents can significantly impede the gastrointestinal functions and subsequently contribute to various gastrointestinal symptoms including nausea and vomiting.Dysfunctions of the stomach,spleen and liver can correspond to specific auricular acupoints,while by stimulating those acupoints,the chaotic Qi movement can be reversed to its normal status,and the hyperactivities of the gastrointestinal system can also be alleviated to reduce the CINV symptoms.Clinical studies based on such theory have well supported the effects of AT on CINV.However,relationships between the traditional theory and the modern medicine understanding of the CINV mechanisms remain unknown and should be further explored in future research.

Traditional Chinese medicine integrated with chemotherapy for stage Ⅳ non-surgical gastric cancer: a retrospective clinical analysis

OBJECTIVE： Traditional Chinese medicine （TCM） is regarded as an important treatment for gastric cancer patients, especially for those in advanced stage. To evaluate the effects of TCM treatment on gastric cancer patients, the authors performed a retrospective study to report the result of the integrated treatment of TCM with chemotherapy for stage IV non-surgical gastric cancer. METHODS： In this study, 182 patients with stage IV and non-surgical gastric cancer were retrospectively analyzed to evaluate the effects of TCM integrated with chemotherapy. Among the 182 cases, 88 cases received integrated therapy consisting of TCM and chemotherapy, while 94 cases received chemotherapy alone. The overall survival and Karnofsky performance status （KPS） score were measured as the main outcome. RESULTS： The median overall survival of the integrated therapy group and chemotherapy group were 16.9 and 10.5 months, respectively. The 1-, 3- and 5-year survival rates of integrated therapy group vs. chemotherapy group were 70% vs. 32%, 18% vs. 4%, and 11% vs. 0%, respectively. There was a significant difference between the two groups （x2 = 42.244, P 〈 0.001 ）. After six-month treatment, KPS scores of the integrated therapy group and the chemotherapy group were 75.00 ± 14.78 and 60.64 ± 21.39, respectively （P 〈 0.001）. The Cox regression analysis showed that TCM treatment is a protective factor for patients＇ overall survival. CONCLUSION： This study demonstrated that TCM integrated with chemotherapy may prolong overal survival and improve survival rate and life quality of patients with stage IV non-surgical gastric cancer

Application of Traditional Chinese Medicine Four-diagnostic auxilia-ry apparatus in evaluation of health status and clinical treatment

OBJECTIVE: To evaluate the application of Traditional Chinese Medicine(TCM) Four-diagnostic Auxiliary Apparatus in disease diagnosis.METHODS: The liver cancer patients and healthy controls were recruited from Shanghai Integrated Chinese and Western Medicine Hospital and Beijing University of Traditional Chinese Medicine, respectively. Then, the included subjects were diagnosed by the Four-diagnostic auxiliary apparatus.RESULTS: Thirty liver cancer patients and 30 paired healthy controls were enrolled in this study. Based on the apparatus, the pulse wave velocity was significantly higher in patients compared with controls(P < 0.05). The number of patients with purple tongue and ecchymosis were more than controls(P < 0.05). The number of patients(10%) with yellow tongue coating were higher than the controls(0%). Patients were inclined to be with water type and fire type constitution.CONCLUSION: TCM Four-diagnostic auxiliary apparatus can be applied in clinical diagnosis of body constitution and health status of subjects. It promotes the accuracy and speed for disease diagnosis and TCM standardization.

培元黜浊汤治疗中晚期肝癌临床观察

目的:观察培元黜浊汤治疗中晚期肝癌患者的临床效果。方法:根据纳入和排除标准筛选中晚期肝癌患者60例,将其随机分为两组各30例。对照组予索拉非尼联合苦参注射液治疗,治疗组在对照组基础上联用培元黜浊汤治疗,疗程为3个月。结果:治疗组的胸闷、善太息,情志抑郁,腹胀,大便溏泄,神疲乏力,纳呆中医证候等级改善优于对照组(P<0.05);且淋巴细胞亚群指标水平与生活质量评分的改善均明显优于对照组。治疗组疾病控制率稍高于对照组,AFP指标水平低于对照组,但差异无统计学意义(P﹥0.05);治疗组不良反应发生率36.67%低于对照组的76.67%(P<0.01)。结论:培元黜浊汤联合索拉非尼治疗中晚期肝癌临床疗效显著,可改善患者免疫功能,提高生活质量。

当归补血汤配合十枣汤治疗肝硬化顽固性腹水患者临床观察

目的探究当归补血汤配合十枣汤在肝硬化顽固性腹水患者临床治疗中的应用效果。方法选取邳州市中医院2021年3月—2022年3月收治的肝硬化顽固性腹水患者60例为研究对象,采取Excel软件随机分为中药组和西药组,各30例,西药组给予常规西药治疗;中药组给予当归补血汤配合十枣汤治疗。比较2组临床疗效。结果中药组治疗效果优于西药组(P<0.05);中药组治疗满意度高于西药组(P<0.05);中药组不良反应发生率低于西药组(P<0.05)。结论肝硬化顽固性腹水患者服用当归补血汤配合十枣汤治疗可显著提升满意度和治疗效果,调节血清电解质水平,值得临床推广。

Chinese medicines for prevention and treatment of human hepatocellular carcinoma: current progress on pharmacological actions and mechanisms

Hepatocellular carcinoma（HCC） is one of leading causes of death in the world. Although various treatments have been developed, the therapeutic side effects are far from desirable. Chinese medicines（CMs, including plants, animal parts and minerals） have drawn a great deal of attention in recent years for their potential in the treatment of HCC. Most studies have shown that CMs may be able to retard HCC progression with multiple actions, either alone or in combination with other conventional therapies to improve quality of life in HCC patients. Additionally, CMs are used for preventing HCC occurrence. The aim of this study is to review the potential prophylactic and curative effects of CMs on human HCC and the possible mechanisms that underlie these pharmacological actions. Publications were collected and reviewed from Pub Med and China National Knowledge Infrastructure from 2000 to 2014. Keywords for literature searches include ＂Chinese medicine＂, ＂Chinese herb＂, ＂traditional Chinese Medicine＂, ＂hepatocellular carcinoma＂ and ＂liver cancer＂. CMs in forms of pure compounds, isolated fractions, and composite formulas are included. Combination therapies are also considered. Both in vitro and in vivo efficacies of CMs are being discussed and the translational potential to bedside is to be discussed with clinical cases, which show the actions of CMs on HCC may include tumor growth inhibition, antimetastatic activities, anti-inflammation, anti-liver cancer stem cells, reversal on multi-drug resistance and induction/reduction of oxidative stress. Multiple types of molecules are found to contribute in the above actions. The review paper indicated that CMs might have potential to both prevent HCC occurrence and retard HCC progression with several molecular targets involved.

参葛方联合生活饮食运动干预治疗肝功能异常代谢相关脂肪性肝病的临床观察

目的观察参葛方联合生活饮食运动干预治疗肝功能异常代谢相关脂肪性肝病(MAFLD)的临床疗效及对患者血清CD44水平的影响。方法将70例脾虚痰湿兼有血瘀型肝功能异常MAFLD患者随机分为对照组和治疗组,每组35例,两组均给予生活饮食运动干预,治疗组加用参葛方,对照组加用参葛方安慰剂,疗程均为12周。观察临床疗效,比较磁共振成像质子密度脂肪含量(MRI-PDFF)及血清丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、碱性磷酸酶(ALP)、γ-谷氨酰转移酶(GGT)、三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、CD44水平的变化情况。结果(1)最终完成试验者64例,其中治疗组32例、对照组32例。(2)治疗组、对照组总有效率分别为75.0%、46.9%,治疗组临床疗效优于对照组(P<0.05)。(3)治疗前后组内比较,两组MRI-PDFF值降低(P<0.05),治疗组血清CD44水平降低(P<0.05);组间治疗后比较,治疗组MRI-PDFF值、血清CD44水平低于对照组(P<0.05)。(4)治疗前后组内比较,治疗组血清ALT、AST、GGT水平降低(P<0.05),对照组AST水平降低(P<0.05);组间治疗后比较,治疗组血清ALT、AST、GGT水平低于对照组(P<0.05)。(5)治疗前后组内比较,治疗组血清TG、TC、LDL水平降低(P<0.05),对照组TG水平降低(P<0.05);组间治疗后比较,治疗组TG水平低于对照组(P<0.05)。结论参葛方联合生活饮食运动干预治疗脾虚痰湿兼有血瘀型肝功能异常MAFLD患者疗效满意,能有效缓解患者的临床症状,改善肝脏脂质沉积及肝功能异常,调节血脂水平,其机制可能与调节血清CD44表达有关。

清热解毒散结方联合肝动脉化疗栓塞术治疗原发性肝癌肝热血瘀型临床研究

目的观察清热解毒散结方联合肝动脉化疗栓塞(TACE)术治疗原发性肝癌肝热血瘀型患者的临床疗效。方法将80例原发性肝癌肝热血瘀型患者按照随机数字表法分为2组,对照组40例予TACE术治疗,治疗组40例在对照组治疗基础上加用清热解毒散结方治疗,2组均连续治疗8周。比较2组临床疗效;比较2组治疗前后总胆红素(TBiL)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、糖类抗原199(CA199)、甲胎蛋白(AFP)水平变化;比较2组治疗前后症状评分变化。结果治疗组总有效率60.0%(24/40),对照组总有效率45.0%(18/40),治疗组临床疗效优于对照组(P<0.05)。2组治疗后TBiL、ALT、AST水平均较本组治疗前降低(P<0.05),治疗后治疗组TBiL、ALT、AST水平均低于对照组(P<0.05)。2组治疗后CA199、AFP水平均较本组治疗前降低(P<0.05),治疗后治疗组CA199、AFP水平均低于对照组(P<0.05)。2组治疗后恶心、肝区疼痛、乏力、纳差评分均较本组治疗前降低(P<0.05),治疗后治疗组恶心、肝区疼痛、乏力、纳差评分均低于对照组(P<0.05)。结论清热解毒散结方联合TACE术治疗原发性肝癌肝热血瘀型,能降低转氨酶水平,促进肝功能恢复,缓解临床症状,减轻术后副作用。

原发性肝癌中医诊疗指南

原发性肝癌是我国最常见的恶性肿瘤之一,严重威胁人民的生命健康。近年来,随着基础及临床研究的开展,原发性肝癌的诊疗手段不断丰富。中医药在原发性肝癌诊疗领域发挥了重要作用,但目前尚无统一的辨治及疗效评价标准。为进一步规范原发性肝癌的中医诊疗,根据中医标准化和相关技术指导文件的要求,起草组通过文献研究、专家访谈、问卷调查、共识会议等方式编写本指南,供临床医师参考。本指南经中华中医药学会批准发布,标准编号:T/CACM 1575—2024。

国医大师周仲瑛辨治肝硬化腹水经验

总结周仲瑛辨治肝硬化腹水的学术经验。中医学认为肝硬化腹水本虚标实,虚实夹杂,正虚邪盛,基本病机是肝失疏泄,脾失健运,肾失气化,致气、血、水互结形成鼓胀。整理分析周仲瑛治疗肝硬化腹水的相关病案,发现湿、热、郁、气滞、血瘀、水停等多种病理因素与肝肾阴虚、脾肾阳虚等正虚证混杂出现,动态演变,呈现复合病机。针对肝硬化腹水的复合病机,周仲瑛强调审机论治,多法并用,灵活运用通利二便法、理气开郁法、清热祛湿法、化瘀通络法、扶正补虚法等,复法组方,随症配伍,临床疗效显著,并附验案2则介绍如下。

痛泻安肠方治疗肝郁脾虚型腹泻型肠易激综合征临床观察

目的明确痛泻安肠方对肝郁脾虚型腹泻型肠易激综合征(IBS-D)的临床疗效和治疗优势。方法采用单中心、随机、阳性药物对照的临床设计开展探索性研究。共纳入36例肝郁脾虚型IBS-D患者,分为2组,每组18例;治疗组予痛泻安肠方,对照组予阳性对照药匹维溴铵片,2组疗程均为4周。观察2组疗效指标和安全性指标。结果治疗组肠易激综合征严重程度评测(IBS-SSS)总评分和中医证候评分低于对照组(P<0.05)。治疗组改善IBS-SSS总有效率、中医证候疗效总有效率为88.89%(16/18)、83.33%(15/18),略高于对照组的83.33%(15/18)、77.78%(14/18),差异无统计学意义(P>0.05)。此外,2组均无明显不良反应发生,安全性检查未见明显异常。结论痛泻安肠方治疗肝郁脾虚型IBS-D安全有效,在改善患者症状方面具有更好的效果。

养阴安神方联合艾司唑仑片治疗老年肝肾阴虚型失眠的临床研究

目的观察养阴安神方联合艾司唑仑片治疗老年肝肾阴虚型失眠的临床疗效。方法将60例老年肝肾阴虚失眠患者按照随机数字表法分为2组,对照组30例予艾司唑仑片治疗,治疗组30例在对照组的基础上联合养阴安神方治疗。2组均治疗4周后统计疗效,比较2组治疗前后中医症状评分、匹兹堡睡眠质量指数(PSQI)(包括睡眠质量、入睡时间、睡眠时间、睡眠效率、睡眠障碍、日间功能障碍及催眠药物)评分及血清白细胞介素6(IL-6)水平变化情况。结果治疗组总有效率90.00%(27/30),对照组总有效率70.00%(21/30),治疗组总有效率高于对照组(P<0.05)。与本组治疗前比较,2组治疗后中医症状评分均降低(P<0.05),且治疗组治疗后中医症状评分低于对照组(P<0.05)。与本组治疗前比较,2组治疗后PSQI睡眠质量、入睡时间、睡眠时间、睡眠效率、睡眠障碍、日间功能障碍及催眠药物评分及总分均降低(P<0.05),且治疗组治疗后PSQI各项评分及总分低于对照组(P<0.05)。与本组治疗前比较,2组治疗后血清IL-6水平均降低(P<0.05),且治疗组治疗后血清IL-6水平低于对照组(P<0.05)。结论养阴安神方联合艾司唑仑片治疗老年肝肾阴虚型失眠临床疗效确切,可有效改善患者中医症状,提高睡眠质量,降低血清IL-6水平,安全可靠。

芪术化积方治疗肝细胞癌癌前病变患者的随机对照研究

背景肝细胞癌(HCC)存在发病率高、死亡率高的特点,在癌前病变阶段进行早期诊断及时干预可有效降低HCC的发生率,对其防治具有显著意义。现代医学对于HCC癌前病变的治疗存在干预时机难以把握、治疗手段单一等问题,中医药防治HCC癌前病变或许是一种简单有效的新途径。目的观察芪术化积方治疗HCC癌前病变(肝郁脾虚、痰瘀互结证)的临床疗效及安全性。方法纳入2019年10月—2020年3月在山东中医药大学附属医院、威海市中医院、泰安市中医院肝病科门诊就医且符合中医证型“肝郁脾虚、痰瘀互结证”的HCC癌前病变初诊患者为研究对象。收集患者的一般资料[性别、年龄、乙型病毒性肝炎(HBV)后肝硬化史、HCC家族史、10年以上饮酒史],患者的中医证候积分、肝功能指标[丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)、白蛋白(ALB)、谷氨酰转肽酶(GGT)、碱性磷酸酶(ALP)]、肿瘤标志物指标[甲胎蛋白(AFP)、甲胎蛋白异质体(AFP-L3)、异常凝血酶原(DCP)]、影像学指标(病灶类型、病灶性质、病灶长径)、安全性指标、不良反应。采用随机数字表法将符合纳入标准且完成研究的64例患者分为观察组(n=34)和对照组(n=30),对照组予以抗病毒、抗炎保肝等常规治疗;观察组予以常规治疗联合芪术化积方治疗。疗程为48周,停药后随访48周,观察两组患者治疗周期及随访周期中HCC发生率及并发症的发生情况,比较两组患者治疗前后中医证候改善指标(中医证候积分、总有效率)、肝功能指标、肿瘤标志物指标、影像学指标(病灶长径、病灶稳定率、病灶改善率)、安全性指标(安全率)的差异。结果治疗后两组中医证候积分、ALT、AST、TBIL、GGT、ALP、AFP-L3均低于治疗前,ALB水平高于治疗前(P<0.05);观察组患者治疗后的DCP值、病灶长径均低于治疗前(P<0.05)。组间比较结果显示,观察组中医证候积分、AST、ALP水平低于对照组,ALB水平高于对照组(P<0.05)。治疗周期结束后观察组的中医证候总有效率(91.2%)高于对照组(63.3%)(P<0.05);观察组病灶改善率(35.3%)和病灶稳定率(50.0%)与对照组(20.0%,43.3%)比较,差异无统计学意义(P>0.05)。随访周期结束后观察组HCC发生率(8.8%)与对照组(16.7%)比较,差异无统计学意义(P>0.05);并发症发生率(8.8%)低于对照组(30.0%)(P<0.05)。安全性指标方面,观察组2例出现轻度不良反应,对照组3例出现轻度不良反应,两组均未出现安全性指标异常,观察组安全率(94.1%)与对照组(90.0%)比较,差异无统计学意义(P>0.05)。结论芪术化积方治疗HCC癌前病变(肝郁脾虚、痰瘀互结证),在改善中医证候、改善肝功能、缩小病灶结节、降低远期HCC发生率及减少肝硬化并发症等方面有较好的临床疗效及安全性。

从肝功能角度探讨中医禁食疗法治疗2型糖尿病的临床研究

目的:随着超重或肥胖的2型糖尿病(Type 2 Diabetes Mellitus,T2DM)的患病群体越来越大,超重或肥胖的T2DM已给患者及其家庭、社会、国家构成了严重经济负担,通过控制体质量进而控制血糖是针对超重或肥胖的T2DM的重要治疗措施。本研究者所在团队创立的中医禁食疗法就是治疗超重或肥胖的T2DM的重要选择,中医禁食疗法通过5 d的禁食结合中药内服及中医综合治疗方法来治疗超重或肥胖的T2DM患者,疗效明显,由于糖、脂类、蛋白质等物质的代谢与肝脏密切相关,在禁食期间,肝脏的代谢负荷会明显增加,肝功能在禁食期间的变化是本研究者所重点关注的方向,本研究的目的是从肝功能角度回顾性研究中医禁食疗法治疗T2DM的安全性与疗效。方法:从既往出院患者中筛选出46例T2DM患者,比较T2DM患者在进行中医禁食疗法治疗前后在空腹血糖、体质量、体质量指数(Body Mass Index,BMI)、肝功能指标(蛋白质代谢功能、胆红素代谢、血清酶)方面的变化情况。结果:46例T2DM患者,进行中医禁食疗法治疗后,在空腹血糖、体质量、体质量指数、总蛋白、球蛋白、γ-谷氨酰基转移酶、碱性磷酸酶、腺苷脱氨酶等方面与治疗前相比明显下降,在天冬氨酸氨基转移酶、总胆红素、直接胆红素、间接胆红素等方面相较于治疗前有上升趋势,而在白蛋白、丙氨酸氨基转移酶、胆碱酯酶、胆汁酸等方面相较于治疗前无显著性改变。结论:中医禁食疗法治疗T2DM安全有效。

健脾扶正汤加减治疗晚期肝癌临床观察

目的 探讨健脾扶正汤加减治疗原发性晚期肝癌的效果以及对癌因性疲乏的影响。方法 选取中国医科大学附属第四医院第二肿瘤内科2019年1月—2021年1月收治的原发性晚期肝癌患者71例作为研究对象,根据随机数字表法分成对照组35例和观察组36例,对照组予以常规西医干预,观察组另给予健脾扶正汤加减治疗,比较2组病灶控制率(DCR)和治疗前后的癌症疲乏量表(CFS)、卡氏功能状态评分量表(KPS)评分及血压等情况。结果 治疗后,观察组DCR为88.89%(32/36),显著高于对照组的68.57%(24/35)(P<0.05);2组CFS评分均显著低于治疗前,观察组较对照组更低(P<0.05);2组KPS评分均显著升高,观察组较对照组更高(P<0.05)。2组收缩压(SBP)、舒张压(DBP)相比差异有统计学意义(P<0.05)。结论健脾扶正汤加减治疗原发性晚期肝癌能提高病灶控制率和辅助降压,同时能缓解癌因性疲乏,对改善患者病情有益。

儿童抽动障碍痰火扰神证的中药治疗

儿童抽动障碍(TD)是一种慢性、反复性神经精神发育障碍性疾病,发病率有逐年升高趋势,越来越受到医学研究与社会关注。近年,中药治疗儿童TD成为更多患者的选择,中医对其病因病机的研究亦愈加深入。多数认为,风、痰是贯穿本病的重要病理因素,因小儿特殊病理、生理特点,儿童TD以痰火扰神证为常见证型。文章对该证型中药治疗进行综述。